LONDON, October 20, 2017 /PRNewswire/ --
The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 206-page report you will receive 66 tables and 59 figures- all unavailable elsewhere.
The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Biomarkers Market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the global biomarkers market by Sector: - Biomarker Services - Biomarker Diagnostics - Biomarker Discovery
• This report also breaks down the revenue forecast for the global biomarkers market by Discipline: - Genomics - Proteomics - Bioinformatics - Other
• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication: - Cancer - Cardiovascular Diseases - CNS, - Autoimmune Diseases - Other
• This report provides individual revenue forecasts to 2027 for these regional and national markets: - US - EU5 (further segmented into France, Germany, the UK, Spain and Italy) - Japan - China - India - Russia - Brazil - RoW
• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.
• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers: - Quintiles IMS Holdings Inc - Laboratory Corporation of America Holdings - Parexel - Charles River Laboratories - ICON plc - WuXi PharmaTec - Caprion Proteomics - Proteome Sciences - Pacific Biomarkers - Oxford Gene Technology (OGT) - Worldwide Clinical Trials (WWC) - Agilent - AB SCIEX - QIAGEN - Axela Inc - Thermo Fisher Scientific - Quest Diagnostics - Myriad Genetics - Genomic Health - Critical Diagnostics - Epigenomics - MDxHealth (formerly OncoMethylome)
• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: - Pfizer - Novartis - Roche Diagnostics - Ventana Medical Systems - Merck & Co. - Sanofi - GSK - Abbott Laboratories - AstraZeneca
Visiongain's study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.
Buy our report today Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/2029/Global-Biomarkers-Market-Forecast-2017-2027
List of Companies Mentioned in the Report
454 Life Sciences (a subsidiary of Roche)
AB SCIEX
Abbott Laboratories
Abbott Molecular
Abcodia
ABT Molecular Imaging
ACS Biomarker
Advanced Cell Diagnostics (ACD)
Advion Bioanalytical Labs (part of Quintiles)
Affymetrix
Agendia
Agilent
Alacris Theranostics
Alere
Amarantus BioSciences
Amgen
Applied Biosystems (part of Life Technologies)
Aptiv Solutions
Arctic Partners
ARIAD Pharmaceuticals
Ariana Pharma
Arizona State University
Arrayit
ARUP Laboratories
AstraZeneca
Athena Diagnostics (a subsidiary of Quest Diagnostics)
Atherotech Diagnostics Lab
Aushon Biosystems
Axela Inc
Bayer
Belfer Institute for Applied Cancer Science [US]
Berkeley HeartLab (a subsidiary of Quest Diagnostics)
BG Medicine
BGI (formerly Beijing Genomics Institute)
Biofortis
Biosoft
BRAHMS (part of Thermo Fisher Scientific)
Brigham and Women's Hospital
Bristol-Myers Squibb
Cancer Research Technology
Caprion Proteomics
CBC (Comprehensive Biomarker Centre GmbH)
Celera (part of Quest Diagnostics)
Celgene
Cell Signaling Technology
Celldex Therapeutics
Cephalon (part of Teva)
Charles River Laboratories
Chronix Biomedical
Chugai Pharmaceutical
Ciphergen Biosystems
Clarient Diagnostic Services
Cleveland HeartLab
Clinigene International
Comprehensive Biomarker Center (formerly Febit)
Covance
Crelux
Critical Diagnostics
Critical Path Institute (C-Path) [US]
CTI Biotech
Daiichi Sankyo
Dako (now part of Agilent)
Dana-Farber Cancer Institute [US]
Danaher
DaVita Labs
DiaGenic
Durin Technologies
DxS (now part of QIAGEN)
EKO Diagnostic
Eli Lilly and Co.
Epic Sciences
Epigenomics
Epistem
EQT
Evotec
Exact Sciences
Exiqon
Exonhit
Ezose Sciences (part of Shionogi)
FEI Company
Foundation Medicine
Fujirebio Diagnostics
GE Healthcare
Genetic Technologies
Geneva Bioinformatics (GeneBio)
Genomic Health
GenWay Biotech
Great Point Partners
GSK
HD Biosciences
Health Diagnostic Laboratory
HealthLinx
Helicos BioSciences
Hewlett-Packard
HTG Molecular Diagnostics
ICON Plc
Illumina
ImmunId
Insight Genetics
Institute of Pathology Heidelberg (IPH)
Integrated Diagnostics
Ipsen
Ipsogen (a subsidiary of QIAGEN)
Isogen Life Science
Johnson & Johnson (J&J)
KU Leuven (University of Leuven)
LabCorp
Life Technologies
LightArray Biotech
M2Gen
Mayo Clinic [US]
Mayo Collaborative Services
MDxHealth
Medical Research Council [UK]
MediMedia Pharma Solutions
Memorial Sloan-Kettering Cancer Center [US]
Merck & Co.
Merck KGaA
Metabolon
Michael J Fox Foundation
Myriad Genetics
Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)
National Academy of Sciences (NAS) [US]
Nephromics
Novartis
Novartis Molecular Diagnostics (part of Novartis)
NovioGendix
Oncoimmune
Oncomedics
OpGen
OPKO Health
Orion Genomics
Oxford Cancer Biomarkers
Oxford Gene Technology
Pacific Biomarkers
Pacific Biosciences
Panomics (now part of Affymetrix)
Parexel
Patheon
Pathwork Diagnostics
Personal Genome Diagnostics
Pfizer
Pierre Fabre
PLUS Diagnostics
PMDA
Power3 Medical Products
PPD
Predictive Biosciences
Prometheus Laboratories
ProtagenAG?
Proteome Sciences
QIAGEN
QLIDA Diagnostics
Quanterix
Quanticel Pharmaceuticals
Quest Diagnostics
Quintiles
Quintiles IMS Holdings Inc
Randox Laboratories
Randox Laboratories
Roche
SABiosciences (now part of QIAGEN)
Sandor Proteomic
Sanger Institute
Sanofi
Santaris Pharma
Servier
Shionogi
Siemens
Siemens Healthcare
Singulex Inc
Sividion Diagnostics
SMA Foundation [US]
Stemina Biomarker Discovery
Sysmex
Technology Strategy Board (TSB) [UK]
Teva Pharmaceutical Industries
Thallion Pharmaceuticals
The Biomarkers Consortium
Thermo Fisher Sciences
Thermo Fisher Scientific
Transgene
Trans-Hit Biomarkers
Tufts Center for the Study of Drug Development
Ventana Medical Systems
Vertex Pharmaceuticals
WaferGen
Warnex
Worldwide Clinical Trials
WuXi AppTec
Wuxi Pharmatech
Xcovery
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
Advertisement
Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases
Advertisement
The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 206-page report you will receive 66 tables and 59 figures- all unavailable elsewhere.
The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Biomarkers Market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the global biomarkers market by Sector: - Biomarker Services - Biomarker Diagnostics - Biomarker Discovery
• This report also breaks down the revenue forecast for the global biomarkers market by Discipline: - Genomics - Proteomics - Bioinformatics - Other
• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication: - Cancer - Cardiovascular Diseases - CNS, - Autoimmune Diseases - Other
• This report provides individual revenue forecasts to 2027 for these regional and national markets: - US - EU5 (further segmented into France, Germany, the UK, Spain and Italy) - Japan - China - India - Russia - Brazil - RoW
• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.
• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers: - Quintiles IMS Holdings Inc - Laboratory Corporation of America Holdings - Parexel - Charles River Laboratories - ICON plc - WuXi PharmaTec - Caprion Proteomics - Proteome Sciences - Pacific Biomarkers - Oxford Gene Technology (OGT) - Worldwide Clinical Trials (WWC) - Agilent - AB SCIEX - QIAGEN - Axela Inc - Thermo Fisher Scientific - Quest Diagnostics - Myriad Genetics - Genomic Health - Critical Diagnostics - Epigenomics - MDxHealth (formerly OncoMethylome)
• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: - Pfizer - Novartis - Roche Diagnostics - Ventana Medical Systems - Merck & Co. - Sanofi - GSK - Abbott Laboratories - AstraZeneca
Visiongain's study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.
Buy our report today Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/2029/Global-Biomarkers-Market-Forecast-2017-2027
List of Companies Mentioned in the Report
454 Life Sciences (a subsidiary of Roche)
AB SCIEX
Abbott Laboratories
Abbott Molecular
Abcodia
ABT Molecular Imaging
ACS Biomarker
Advanced Cell Diagnostics (ACD)
Advion Bioanalytical Labs (part of Quintiles)
Affymetrix
Agendia
Agilent
Alacris Theranostics
Alere
Amarantus BioSciences
Amgen
Applied Biosystems (part of Life Technologies)
Aptiv Solutions
Arctic Partners
ARIAD Pharmaceuticals
Ariana Pharma
Arizona State University
Arrayit
ARUP Laboratories
AstraZeneca
Athena Diagnostics (a subsidiary of Quest Diagnostics)
Atherotech Diagnostics Lab
Aushon Biosystems
Axela Inc
Bayer
Belfer Institute for Applied Cancer Science [US]
Berkeley HeartLab (a subsidiary of Quest Diagnostics)
BG Medicine
BGI (formerly Beijing Genomics Institute)
Biofortis
Biosoft
BRAHMS (part of Thermo Fisher Scientific)
Brigham and Women's Hospital
Bristol-Myers Squibb
Cancer Research Technology
Caprion Proteomics
CBC (Comprehensive Biomarker Centre GmbH)
Celera (part of Quest Diagnostics)
Celgene
Cell Signaling Technology
Celldex Therapeutics
Cephalon (part of Teva)
Charles River Laboratories
Chronix Biomedical
Chugai Pharmaceutical
Ciphergen Biosystems
Clarient Diagnostic Services
Cleveland HeartLab
Clinigene International
Comprehensive Biomarker Center (formerly Febit)
Covance
Crelux
Critical Diagnostics
Critical Path Institute (C-Path) [US]
CTI Biotech
Daiichi Sankyo
Dako (now part of Agilent)
Dana-Farber Cancer Institute [US]
Danaher
DaVita Labs
DiaGenic
Durin Technologies
DxS (now part of QIAGEN)
EKO Diagnostic
Eli Lilly and Co.
Epic Sciences
Epigenomics
Epistem
EQT
Evotec
Exact Sciences
Exiqon
Exonhit
Ezose Sciences (part of Shionogi)
FEI Company
Foundation Medicine
Fujirebio Diagnostics
GE Healthcare
Genetic Technologies
Geneva Bioinformatics (GeneBio)
Genomic Health
GenWay Biotech
Great Point Partners
GSK
HD Biosciences
Health Diagnostic Laboratory
HealthLinx
Helicos BioSciences
Hewlett-Packard
HTG Molecular Diagnostics
ICON Plc
Illumina
ImmunId
Insight Genetics
Institute of Pathology Heidelberg (IPH)
Integrated Diagnostics
Ipsen
Ipsogen (a subsidiary of QIAGEN)
Isogen Life Science
Johnson & Johnson (J&J)
KU Leuven (University of Leuven)
LabCorp
Life Technologies
LightArray Biotech
M2Gen
Mayo Clinic [US]
Mayo Collaborative Services
MDxHealth
Medical Research Council [UK]
MediMedia Pharma Solutions
Memorial Sloan-Kettering Cancer Center [US]
Merck & Co.
Merck KGaA
Metabolon
Michael J Fox Foundation
Myriad Genetics
Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)
National Academy of Sciences (NAS) [US]
Nephromics
Novartis
Novartis Molecular Diagnostics (part of Novartis)
NovioGendix
Oncoimmune
Oncomedics
OpGen
OPKO Health
Orion Genomics
Oxford Cancer Biomarkers
Oxford Gene Technology
Pacific Biomarkers
Pacific Biosciences
Panomics (now part of Affymetrix)
Parexel
Patheon
Pathwork Diagnostics
Personal Genome Diagnostics
Pfizer
Pierre Fabre
PLUS Diagnostics
PMDA
Power3 Medical Products
PPD
Predictive Biosciences
Prometheus Laboratories
ProtagenAG?
Proteome Sciences
QIAGEN
QLIDA Diagnostics
Quanterix
Quanticel Pharmaceuticals
Quest Diagnostics
Quintiles
Quintiles IMS Holdings Inc
Randox Laboratories
Randox Laboratories
Roche
SABiosciences (now part of QIAGEN)
Sandor Proteomic
Sanger Institute
Sanofi
Santaris Pharma
Servier
Shionogi
Siemens
Siemens Healthcare
Singulex Inc
Sividion Diagnostics
SMA Foundation [US]
Stemina Biomarker Discovery
Sysmex
Technology Strategy Board (TSB) [UK]
Teva Pharmaceutical Industries
Thallion Pharmaceuticals
The Biomarkers Consortium
Thermo Fisher Sciences
Thermo Fisher Scientific
Transgene
Trans-Hit Biomarkers
Tufts Center for the Study of Drug Development
Ventana Medical Systems
Vertex Pharmaceuticals
WaferGen
Warnex
Worldwide Clinical Trials
WuXi AppTec
Wuxi Pharmatech
Xcovery
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
